In this episode, David Drapkin interviews David Nutt: Psychiatrist, Founder and Chief Scientific Officer at Drug Science, Chief Research Officer at Awakn Life Sciences, and Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London. After a successful study on MDMA in the treatment of alcohol use disorder, Nutt is looking into if improvements can be made to MDMA. He discusses how serotonin seems to affect the default mode network; Robin Carhart-Harris’ “Trial of Psilocybin versus Escitalopram for Depression” study and the realization that psychedelics were doing something different in the brain; Measure 109 and the importance of how Oregon establishes a new paradigm around legal mushrooms; drug hysteria in the US and UK and how drastically that differs from Portugal’s incredibly successful approach to drugs; why real world evidence is the core of science; and why psychedelics seem best at disrupting internalizing disorders.

The post PT334 – Prof. David Nutt – The Human Brain, Addiction, and Telling the Truth About Drugs appeared first on Psychedelics Today.

Previous articlePharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
Next articleBetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies